VolitionRx Files to Sell 17.97M Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy VNRX?
VolitionRx files to sell 17.97M shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.203
Low
1.50
Averages
2.25
High
3.00
Current: 0.203
Low
1.50
Averages
2.25
High
3.00
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VolitionRx Receives NYSE Compliance Notice
- Compliance Warning: VolitionRx received a notice from NYSE American indicating non-compliance with continued listing standards, requiring at least $2 million in stockholders' equity, highlighting the company's financial vulnerabilities amid reported losses in two of the last three fiscal years.
- Remediation Plan Requirement: The company must submit a plan to NYSE by March 8, 2026, detailing actions taken to regain compliance by August 6, 2027, which could impact future financing and operational strategies as they navigate this challenge.
- Listing Status Unchanged: Despite the warning, the company's shares will continue to be listed and traded on NYSE American during this period, indicating no immediate impact on shareholders, although long-term compliance remains a concern.
- Stock Price Fluctuation: Following the notice, VNRX's stock price fell 0.67% in after-hours trading to $0.251, reflecting market concerns over the company's financial health, which may affect investor confidence and future financing capabilities.
See More
Venus Concept Inc. Announces Voluntary Delisting from NASDAQ to Cut Compliance Costs
- Voluntary Delisting Decision: Venus Concept has decided to voluntarily delist from NASDAQ, with the last trading day expected on February 6, 2026, aiming to reduce compliance costs to support the company's turnaround plan.
- Compliance Cost Consideration: The Board of Directors concluded that the resources required to continue SEC reporting obligations outweigh the benefits of NASDAQ listing, making this strategic decision to utilize resources more effectively.
- Next Steps Arrangement: The company plans to file Form 25 with the SEC on January 30, 2026, followed by Form 15 on February 9, 2026, which will immediately suspend its periodic reporting obligations, further streamlining operational processes.
- Commitment to Long-Term Financial Success: CEO Rajiv De Silva stated that this move will assist the company in collaborating with Madryn Asset Management to drive sustained long-term financial success.
See More
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
- Significant Market Opportunity: VolitionRx's Nu.Q® Vet cancer detection tool has a total addressable market of approximately $100 million in the U.S., Europe, and Japan, which could rise to nearly $150 million with the inclusion of China, indicating vast potential in the global pet health sector.
- Detection Technology Promotion: By partnering with new centralized laboratories, VolitionRx integrates the Nu.Q® Canine Cancer Test into annual checkups and senior wellness exams, enabling veterinarians to detect cancer earlier, thus assisting pet owners in making timely treatment decisions and enhancing the quality of veterinary care.
- International Expansion: This expansion not only strengthens Volition's market presence in the U.S. and Asia but also enhances its competitiveness in the global early cancer detection market for pets through collaborations with established laboratories, further solidifying its industry leadership.
- Strategic Development Direction: VolitionRx is committed to improving the quality of life for humans and animals through early detection and disease monitoring, and this technology rollout aligns with its overall strategy aimed at driving long-term growth through innovation.
See More
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
- Significant Market Opportunity: VolitionRx's Nu.Q® Vet cancer test presents a total addressable market of approximately $100 million in the U.S. and Europe, potentially rising to nearly $150 million with the inclusion of China, highlighting the company's growth potential in pet health.
- Laboratory Partnership Expansion: Starting February 2026, Midwest Veterinary Laboratory will offer the Nu.Q® Vet cancer test across all 50 states in the U.S., while Bioguard will provide the test through its Animal Health Diagnostic Center in Taiwan and China, significantly enhancing product accessibility.
- Early Detection Benefits: By incorporating the Nu.Q® canine cancer test into annual check-ups, veterinarians can detect cancer earlier, enabling pet owners to make timely, informed decisions about cancer care, thereby improving survival rates and quality of life for pets.
- Commitment to Technological Innovation: VolitionRx is dedicated to advancing health outcomes through its innovative blood testing technology, emphasizing its strategic importance in early disease detection and monitoring, which further solidifies its leadership position in the biotechnology sector.
See More
VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test
- Industry Symposium Sponsorship: VolitionRx sponsors the Veterinary Meeting and Expo (VMX 2026) in Orlando, Florida, expected to attract around 20,000 veterinary professionals, enhancing brand visibility and facilitating engagement with industry experts.
- Cancer Detection Promotion: Dr. Sue Ettinger will present the Nu.Q® Vet Cancer Test at the conference, emphasizing its application in early cancer detection, enabling veterinarians to identify cancer sooner during annual check-ups, thus improving pet owners' decision-making capabilities.
- Market Opportunity Capture: By showcasing the Nu.Q® Test, VolitionRx not only demonstrates its innovative capabilities in veterinary diagnostics but also potentially drives future revenue growth by increasing market acceptance, further solidifying its market position.
- R&D Strategic Layout: VolitionRx is committed to enhancing early detection capabilities for cancer and other diseases through simple, cost-effective blood testing technologies, aiming to improve the quality of life for both animals and humans, showcasing its long-term development potential in the life sciences sector.
See More
VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test
- Industry Symposium Sponsorship: VolitionRx sponsors the VMX 2026 veterinary conference in Orlando, Florida, expected to attract around 20,000 veterinary professionals, showcasing the potential of its Nu.Q® Vet Cancer Test and enhancing brand visibility.
- Expert Presentation: Renowned veterinary oncologist Dr. Sue Ettinger will present on January 19 how to utilize the Nu.Q® Vet Cancer Test in practice, aiding veterinarians in earlier cancer detection, thereby improving treatment decisions and outcomes for pets.
- Market Opportunity: By incorporating the Nu.Q® Canine Cancer Test into annual checkups and senior wellness exams, VolitionRx aims to enhance veterinarians' cancer detection capabilities, driving growth in the veterinary diagnostics market.
- Booth Showcase: The Volition Veterinary Diagnostics Development team will showcase its innovative products at booth 2243, leveraging this opportunity to engage with industry partners, further expanding market share and enhancing customer relationships.
See More
VolitionRx Receives NYSE Compliance Notice
- Compliance Warning: VolitionRx received a notice from NYSE American indicating non-compliance with continued listing standards, requiring at least $2 million in stockholders' equity, highlighting the company's financial vulnerabilities amid reported losses in two of the last three fiscal years.
- Remediation Plan Requirement: The company must submit a plan to NYSE by March 8, 2026, detailing actions taken to regain compliance by August 6, 2027, which could impact future financing and operational strategies as they navigate this challenge.
- Listing Status Unchanged: Despite the warning, the company's shares will continue to be listed and traded on NYSE American during this period, indicating no immediate impact on shareholders, although long-term compliance remains a concern.
- Stock Price Fluctuation: Following the notice, VNRX's stock price fell 0.67% in after-hours trading to $0.251, reflecting market concerns over the company's financial health, which may affect investor confidence and future financing capabilities.
See More
Venus Concept Inc. Announces Voluntary Delisting from NASDAQ to Cut Compliance Costs
- Voluntary Delisting Decision: Venus Concept has decided to voluntarily delist from NASDAQ, with the last trading day expected on February 6, 2026, aiming to reduce compliance costs to support the company's turnaround plan.
- Compliance Cost Consideration: The Board of Directors concluded that the resources required to continue SEC reporting obligations outweigh the benefits of NASDAQ listing, making this strategic decision to utilize resources more effectively.
- Next Steps Arrangement: The company plans to file Form 25 with the SEC on January 30, 2026, followed by Form 15 on February 9, 2026, which will immediately suspend its periodic reporting obligations, further streamlining operational processes.
- Commitment to Long-Term Financial Success: CEO Rajiv De Silva stated that this move will assist the company in collaborating with Madryn Asset Management to drive sustained long-term financial success.
See More
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
- Significant Market Opportunity: VolitionRx's Nu.Q® Vet cancer detection tool has a total addressable market of approximately $100 million in the U.S., Europe, and Japan, which could rise to nearly $150 million with the inclusion of China, indicating vast potential in the global pet health sector.
- Detection Technology Promotion: By partnering with new centralized laboratories, VolitionRx integrates the Nu.Q® Canine Cancer Test into annual checkups and senior wellness exams, enabling veterinarians to detect cancer earlier, thus assisting pet owners in making timely treatment decisions and enhancing the quality of veterinary care.
- International Expansion: This expansion not only strengthens Volition's market presence in the U.S. and Asia but also enhances its competitiveness in the global early cancer detection market for pets through collaborations with established laboratories, further solidifying its industry leadership.
- Strategic Development Direction: VolitionRx is committed to improving the quality of life for humans and animals through early detection and disease monitoring, and this technology rollout aligns with its overall strategy aimed at driving long-term growth through innovation.
See More
VolitionRx Expands Nu.Q® Vet Cancer Test Access in U.S. and Asia
- Significant Market Opportunity: VolitionRx's Nu.Q® Vet cancer test presents a total addressable market of approximately $100 million in the U.S. and Europe, potentially rising to nearly $150 million with the inclusion of China, highlighting the company's growth potential in pet health.
- Laboratory Partnership Expansion: Starting February 2026, Midwest Veterinary Laboratory will offer the Nu.Q® Vet cancer test across all 50 states in the U.S., while Bioguard will provide the test through its Animal Health Diagnostic Center in Taiwan and China, significantly enhancing product accessibility.
- Early Detection Benefits: By incorporating the Nu.Q® canine cancer test into annual check-ups, veterinarians can detect cancer earlier, enabling pet owners to make timely, informed decisions about cancer care, thereby improving survival rates and quality of life for pets.
- Commitment to Technological Innovation: VolitionRx is dedicated to advancing health outcomes through its innovative blood testing technology, emphasizing its strategic importance in early disease detection and monitoring, which further solidifies its leadership position in the biotechnology sector.
See More
VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test
- Industry Symposium Sponsorship: VolitionRx sponsors the Veterinary Meeting and Expo (VMX 2026) in Orlando, Florida, expected to attract around 20,000 veterinary professionals, enhancing brand visibility and facilitating engagement with industry experts.
- Cancer Detection Promotion: Dr. Sue Ettinger will present the Nu.Q® Vet Cancer Test at the conference, emphasizing its application in early cancer detection, enabling veterinarians to identify cancer sooner during annual check-ups, thus improving pet owners' decision-making capabilities.
- Market Opportunity Capture: By showcasing the Nu.Q® Test, VolitionRx not only demonstrates its innovative capabilities in veterinary diagnostics but also potentially drives future revenue growth by increasing market acceptance, further solidifying its market position.
- R&D Strategic Layout: VolitionRx is committed to enhancing early detection capabilities for cancer and other diseases through simple, cost-effective blood testing technologies, aiming to improve the quality of life for both animals and humans, showcasing its long-term development potential in the life sciences sector.
See More
VolitionRx Sponsors VMX 2026, Showcases Nu.Q® Vet Cancer Test
- Industry Symposium Sponsorship: VolitionRx sponsors the VMX 2026 veterinary conference in Orlando, Florida, expected to attract around 20,000 veterinary professionals, showcasing the potential of its Nu.Q® Vet Cancer Test and enhancing brand visibility.
- Expert Presentation: Renowned veterinary oncologist Dr. Sue Ettinger will present on January 19 how to utilize the Nu.Q® Vet Cancer Test in practice, aiding veterinarians in earlier cancer detection, thereby improving treatment decisions and outcomes for pets.
- Market Opportunity: By incorporating the Nu.Q® Canine Cancer Test into annual checkups and senior wellness exams, VolitionRx aims to enhance veterinarians' cancer detection capabilities, driving growth in the veterinary diagnostics market.
- Booth Showcase: The Volition Veterinary Diagnostics Development team will showcase its innovative products at booth 2243, leveraging this opportunity to engage with industry partners, further expanding market share and enhancing customer relationships.
See More
